CN114306108A - Nursing agent for balancing gynecological microecological flora structure - Google Patents
Nursing agent for balancing gynecological microecological flora structure Download PDFInfo
- Publication number
- CN114306108A CN114306108A CN202210047461.9A CN202210047461A CN114306108A CN 114306108 A CN114306108 A CN 114306108A CN 202210047461 A CN202210047461 A CN 202210047461A CN 114306108 A CN114306108 A CN 114306108A
- Authority
- CN
- China
- Prior art keywords
- acid
- composition
- acetic acid
- butyric
- lactic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000474 nursing effect Effects 0.000 title claims abstract description 13
- 239000000203 mixture Substances 0.000 claims abstract description 74
- 150000001719 carbohydrate derivatives Chemical class 0.000 claims abstract description 31
- 150000007524 organic acids Chemical class 0.000 claims abstract description 29
- 150000001720 carbohydrates Chemical group 0.000 claims abstract description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 25
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 19
- 239000003906 humectant Substances 0.000 claims abstract description 6
- 239000004094 surface-active agent Substances 0.000 claims abstract description 6
- 239000002562 thickening agent Substances 0.000 claims abstract description 6
- 239000003755 preservative agent Substances 0.000 claims abstract description 5
- 230000002335 preservative effect Effects 0.000 claims abstract description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 153
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 106
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 96
- 239000004310 lactic acid Substances 0.000 claims description 53
- 235000014655 lactic acid Nutrition 0.000 claims description 53
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 42
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 25
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 25
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 25
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 24
- 239000008103 glucose Substances 0.000 claims description 24
- JDRSMPFHFNXQRB-CMTNHCDUSA-N Decyl beta-D-threo-hexopyranoside Chemical compound CCCCCCCCCCO[C@@H]1O[C@H](CO)C(O)[C@H](O)C1O JDRSMPFHFNXQRB-CMTNHCDUSA-N 0.000 claims description 19
- 229940073499 decyl glucoside Drugs 0.000 claims description 19
- -1 small molecule organic acids Chemical class 0.000 claims description 12
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 8
- 235000005985 organic acids Nutrition 0.000 claims description 7
- 239000003973 paint Substances 0.000 claims 1
- 241000894006 Bacteria Species 0.000 abstract description 22
- 230000000694 effects Effects 0.000 abstract description 22
- 241000191967 Staphylococcus aureus Species 0.000 abstract description 14
- 241000222122 Candida albicans Species 0.000 abstract description 13
- 241000588724 Escherichia coli Species 0.000 abstract description 13
- 229940095731 candida albicans Drugs 0.000 abstract description 13
- 241000186660 Lactobacillus Species 0.000 abstract description 12
- 241000193985 Streptococcus agalactiae Species 0.000 abstract description 12
- 239000006041 probiotic Substances 0.000 abstract description 9
- 235000018291 probiotics Nutrition 0.000 abstract description 9
- 229940039696 lactobacillus Drugs 0.000 abstract description 8
- 230000003385 bacteriostatic effect Effects 0.000 abstract description 6
- 230000000529 probiotic effect Effects 0.000 abstract description 6
- 210000005000 reproductive tract Anatomy 0.000 abstract description 6
- 230000001954 sterilising effect Effects 0.000 abstract description 5
- 238000004659 sterilization and disinfection Methods 0.000 abstract description 5
- 238000003756 stirring Methods 0.000 description 35
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 33
- 239000011259 mixed solution Substances 0.000 description 25
- 241000218492 Lactobacillus crispatus Species 0.000 description 17
- 239000002253 acid Substances 0.000 description 16
- 239000000306 component Substances 0.000 description 15
- 239000000499 gel Substances 0.000 description 15
- 239000001963 growth medium Substances 0.000 description 15
- 238000009630 liquid culture Methods 0.000 description 11
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 11
- 239000004299 sodium benzoate Substances 0.000 description 11
- 235000010234 sodium benzoate Nutrition 0.000 description 11
- 239000000230 xanthan gum Substances 0.000 description 11
- 229920001285 xanthan gum Polymers 0.000 description 11
- 235000010493 xanthan gum Nutrition 0.000 description 11
- 229940082509 xanthan gum Drugs 0.000 description 11
- 238000009472 formulation Methods 0.000 description 10
- 239000006210 lotion Substances 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 230000001580 bacterial effect Effects 0.000 description 8
- 239000002609 medium Substances 0.000 description 7
- 230000000844 anti-bacterial effect Effects 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 6
- 229940057950 sodium laureth sulfate Drugs 0.000 description 6
- SXHLENDCVBIJFO-UHFFFAOYSA-M sodium;2-[2-(2-dodecoxyethoxy)ethoxy]ethyl sulfate Chemical compound [Na+].CCCCCCCCCCCCOCCOCCOCCOS([O-])(=O)=O SXHLENDCVBIJFO-UHFFFAOYSA-M 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 241000208818 Helianthus Species 0.000 description 5
- 235000003222 Helianthus annuus Nutrition 0.000 description 5
- 244000052616 bacterial pathogen Species 0.000 description 5
- 229930182478 glucoside Natural products 0.000 description 5
- 150000008131 glucosides Chemical class 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 208000004926 Bacterial Vaginosis Diseases 0.000 description 4
- 208000037009 Vaginitis bacterial Diseases 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 201000007096 Vulvovaginal Candidiasis Diseases 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 201000009273 Endometriosis Diseases 0.000 description 2
- 230000005526 G1 to G0 transition Effects 0.000 description 2
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 208000007074 Trichomonas Vaginitis Diseases 0.000 description 2
- 208000025206 Trichomonas vaginitis urogenital infection Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 229960002227 clindamycin Drugs 0.000 description 2
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000008358 core component Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010013470 Dissociative states Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000004145 Endometritis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010061977 Genital infection female Diseases 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 239000006159 Sabouraud's agar Substances 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical group [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229940069521 aloe extract Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 229960001668 cefuroxime Drugs 0.000 description 1
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 229940080421 coco glucoside Drugs 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000214 effect on organisms Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 150000007660 quinolones Chemical class 0.000 description 1
- 239000012449 sabouraud dextrose agar Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
Images
Landscapes
- Cosmetics (AREA)
Abstract
The invention provides a nursing agent for balancing the structure of gynecological microecological flora, which comprises water, a surfactant, a humectant, a preservative and a thickening agent, wherein core functional components comprise a composition of micromolecular organic acid and a composition of saccharides and saccharide derivatives. The nursing agent realizes the obvious sterilization effect on Escherichia coli, staphylococcus aureus and streptococcus agalactiae, has the obvious bacteriostatic effect on Candida albicans, effectively inhibits the growth of harmful bacteria, can also promote the growth of probiotic lactobacillus in the genital tract, and really plays a role in balancing healthy microecological flora.
Description
Technical Field
The invention relates to the technical field of female nursing agents, in particular to a nursing agent for balancing a gynecological microecological flora structure.
Background
In the vagina of healthy women of child bearing age, lactobacillus is taken as the dominant bacterium, and the acidic substances and the antibacterial substances secreted by the lactobacillus can resist the colonization infection of exogenous pathogenic bacteria, thereby playing an important role in maintaining the normal vaginal micro-ecological environment. When the lactobacilli are reduced and other bacteria are excessively propagated, the imbalance of the vaginal flora is caused. It is commonly known as Aerobic Vaginitis (AV), Bacterial Vaginosis (BV), Trichomonas Vaginitis (TV), vulvovaginal candidiasis (VVC), etc., and serious ascending infection of pathogenic bacteria may also cause Pelvic Inflammatory Disease (PID), endometritis (endometris), Endometriosis (EMS), etc.
Aiming at various infections caused by vaginal microecological disorder, currently, the clinical application mainly adopts external or internal antibiotic medicines, such as clindamycin, cefuroxime, quinolones and the like for treating AV; metronidazole, clindamycin and the like are commonly used for treating BV; clotrimazole, miconazole, nystatin and the like are commonly used for treating VVC, and the antibiotics kill probiotic lactobacillus in the process of killing harmful bacteria, so that the balance of microecological flora is destroyed, and further serious consequences such as relapse and drug resistance are caused.
At present, a plurality of nursing agents or gel products and patents aiming at gynecological infection exist, and related main functional components mainly comprise a broad-spectrum antibacterial disinfectant with a single functional component, such as a chlorine-containing compound (CN103446177A), an antibacterial substance with mixed functional components, such as a traditional Chinese medicine or a traditional Chinese medicine extract (CN101099815A), a plant essence (CN107913397A) and lactobacillus or other bacterial secretion (CN 201110179138.9). The products or components can inhibit the growth of common pathogenic bacteria such as Escherichia coli and staphylococcus aureus, compared with chlorine-containing compounds, although the irritation of the mixed extract of plant sources or probiotic sources to the skin is greatly improved, the problem of poor antibacterial specificity still exists, the mixed extract also has strong inhibiting effect on some self beneficial bacteria such as lactobacillus, and is not beneficial to daily washing and nursing to prevent infection.
Although the influence of lotion on probiotics is concerned, the effect of inhibiting the bacteria of the lotion is weak, the growth of the lactobacilli cannot be really promoted, which is slightly different from the natural situation in the vaginal environment, probably because the exogenous additive component only concerns simple factors such as bacteria inhibition or pH value and the like, the inhibition effect on the vaginal microenvironment and probiotics is caused in the process of inhibiting harmful bacteria, the inhibition effect cannot be really relieved after long-term use, and adverse effects such as low activity of probiotics in the genital tract, fragile vaginal microecology, reduced pathogen resistance and the like are caused.
Disclosure of Invention
The invention mainly solves the problems that most of the existing gynecological lotion or gel core component formulas play a role in inhibiting and killing bacteria aiming at harmful bacteria, the protection and growth promotion effects on the reproductive tract probiotic lactobacillus are neglected, the reproductive tract barrier mainly comprising the lactobacillus cannot be effectively promoted, and the healthy microecological flora cannot be truly balanced.
Based on the problems, the technical scheme provided by the invention is a nursing agent for balancing the structure of gynecological microecological flora, which comprises water, a surfactant, a humectant, a preservative and a thickening agent, wherein the core functional component comprises a composition of small-molecule organic acid and a composition of saccharides and saccharide derivatives.
Wherein the surfactant can be sodium laureth sulfate, tea saponin, coco glucoside, etc., the humectant can be glycerol, sorbitol, aloe extract, etc., the thickener can be sodium carboxymethylcellulose, nonionic guar gum, xanthan gum, etc., and the antiseptic can be sodium benzoate.
The components are as follows by weight: 1.5-5 parts of a small-molecular organic acid composition; 1.5-5 parts of a composition of saccharides and saccharide derivatives; 0-15 parts of a surfactant; 8-10 parts of a humectant; 0.5-1 part of a thickening agent; 0.8-1 part of preservative; 60-88 parts of water.
Wherein the composition of the small molecule organic acid is a combination of at least two of lactic acid, acetic acid, butyric acid or citric acid.
Organic acids, an important class of products for many microorganisms, have mostly been demonstrated to have bacteriostatic effects. At present, the bacteriostatic mechanism of organic acid is yet to be further defined, and it is generally considered that the bacteriostatic mechanism of organic acid has the effects of lowering the pH of the environment, providing an acidic environment, destroying the morphological structure of bacterial cells, and breaking the activity of biochemical metabolic enzyme. The pH affects the dissociation degree of organic acid, which is not easy to dissociate under low pH condition, while non-dissociative acid molecules easily penetrate microbial membrane to dissociate in cells, acidify cytoplasm and cause the death of microbes. The pKa of acetic acid is greater than that of lactic acid, the acetic acid is relatively easier to maintain in a non-dissociative state, the volume of the acetic acid is smaller, the lipid solubility is better, and theoretical bacteriostasis is stronger, but actually, the acetic acid treatment with the acetic acid content of pH4.5 and 0.8M (5% w/v) only inhibits part of BV-related bacteria, which indicates that the inhibition mechanism of lactic acid on bacteria has other aspects, and also indicates that the inhibition mechanisms of different organic acids have differences. In the micro-ecological environment, different organic acid compositions and proportions have different inhibitory effects on conditional pathogenic bacteria.
Further, the composition of the small molecule organic acid in weight percentage is lactic acid (0.1%), acetic acid (0.1%) and butyric acid (0.1%) or lactic acid (0.5%), acetic acid (0.1%) and butyric acid (0.1%), lactic acid (0.5%) and citric acid (0.5%), lactic acid (0.5%), citric acid (0.1%) and butyric acid (0.5%) or lactic acid (0.1%), acetic acid (0.5%) and butyric acid (0.5%) or lactic acid (0.1%), a combination of acetic acid (1%) and butyric acid (1%) or a combination of lactic acid (0.5%), acetic acid (0.5%) and butyric acid (1.5%) or a combination of lactic acid (0.5%), acetic acid (0.5%), butyric acid (1%) and citric acid (0.1%) or a combination of lactic acid (1.0%), acetic acid (1.5%) and butyric acid (0.5%) or a combination of lactic acid (1.0%), acetic acid (1%) and butyric acid (1%).
Preferably, the composition of the small molecule organic acid in weight percentage is a combination of lactic acid (0.5%), acetic acid (0.5%) and butyric acid (1.5%) or a combination of lactic acid (0.5%), acetic acid (0.5%), butyric acid (1%) and citric acid (0.1%) or a combination of lactic acid (1.0%), acetic acid (1.5%) and butyric acid (0.5%) or a combination of lactic acid (1.0%), acetic acid (1%) and butyric acid (1%).
More preferably, the composition of the small molecule organic acid in weight percentage is a combination of lactic acid (1.0%), acetic acid (1.5%) and butyric acid (0.5%) or a combination of lactic acid (1.0%), acetic acid (1%) and butyric acid (1%).
Wherein the composition of the saccharides and saccharide derivatives is a combination of glucose, trehalose and decyl glucoside. Glucose is a main functional substance of organisms, is necessary for the growth of microorganisms, and trehalose is known as 'life sugar' and is a typical stress metabolite formed by the organisms for the change of external environment, so that the organisms are protected against the external severe environment. Exogenous trehalose also has a nonspecific protection effect on organisms, and the part of the organism containing trehalose strongly binds water molecules and has the function of combining water with membrane lipid or replacing membrane-combined water by the trehalose, so that the denaturation of biological membranes and membrane proteins is prevented. The decyl glucoside is catalyzed by glucose, can disperse the combination of lipid and water, prevent the aggregation of saccharide and fatty acid, stabilize protein at low concentration, promote the dispersion of saccharide in flora to a certain extent, and increase the absorbability.
Further, the composition of the small molecular organic acid and the composition of the saccharide and the saccharide derivative are combined according to the weight percentage as follows: lactic acid (0.5%), acetic acid (0.5%), butyric acid (1.5%), glucose (0.5%), trehalose (0.5%) and decyl glucoside (0.1%) or lactic acid (0.5%), acetic acid (0.5%), butyric acid (1%), citric acid (0.1%), glucose (1%), trehalose (1%) and decyl glucoside (0.5%) or lactic acid (1.0%), acetic acid (1.5%), butyric acid (0.5%), glucose (1%), trehalose (1%) and decyl glucoside (0.5%) or lactic acid (1.0%), acetic acid (1%), butyric acid (1%), glucose (1%), trehalose (1%) and decyl glucoside (0.1%) or lactic acid (1.0%), acetic acid (1%), butyric acid (1%), glucose (0.5%), trehalose (1%) and decyl glucoside (0.1%).
Preferably, the composition of the small molecule organic acid and the composition of the saccharide and the saccharide derivative are combined by weight percentage as follows: lactic acid (1.0%), acetic acid (1%), butyric acid (1%), glucose (1%), trehalose (1%) and decyl glucoside (0.1%) or lactic acid (1.0%), acetic acid (1%), butyric acid (1%), glucose (0.5%), trehalose (1%) and decyl glucoside (0.1%).
The core component of the nursing agent is the combination of the small-molecule organic acid composition and the saccharide and saccharide derivative composition, and only after the saccharide and saccharide derivative composition is added into the organic acid composition, the nursing agent can ensure that the lotion can effectively inhibit the growth of harmful bacteria in the urogenital tract and can promote the growth of probiotic lactobacilli in the genital tract, thereby really playing a role in balancing micro-ecological flora.
The following experimental comparisons show that:
1) strain culture: as shown in table 1:
TABLE 1 strains for validation and culture conditions thereof
Bacterial strains | Agar plate culture medium | Liquid culture medium | Culture temperature/. degree.C | Cultivation time/h |
Escherichia coli | Columbia blood plate | TSB liquid culture medium | 37 | 24 |
Staphylococcus aureus | Columbia blood plate | TSB liquid culture medium | 37 | 24 |
Streptococcus agalactiae | Columbia blood plate | TSB liquid culture medium | 37 | 48 |
Candida albicans | Sabouraud agar plate | Sabouraud's liquid culture medium | 27 | 48 |
Lactobacillus crispatus | MRS flat plate | MRS liquid medium | 37 | 48 |
2) Preparing a bacterial suspension: freshly cultured single colonies were picked and mixed well in 1mL of 1 XPBS to prepare absorbance OD600The bacterial suspension was 0.5.
3) Preparing a culture medium: MRS liquid medium, TSB liquid medium, and Sabouraud's liquid medium powder were weighed in the reference medium specification, dissolved with water, and sterilized at 115 ℃ for 15 minutes. Respectively utilizing lactic acid, acetic acid, succinic acid, citric acid and butyric acid to regulate the volume ratio content (v/v) of 5 acids in the MRS liquid culture medium, the TSB liquid culture medium and the Sa's liquid culture medium, so that the culture medium contains the multi-component organic acid, and respectively utilizing lactic acid, acetic acid, succinic acid, citric acid, butyric acid, glucose, trehalose and sunflower-based glucoside to regulate the volume ratio content (v/v) of 5 acids and saccharides in the MRS liquid culture medium, the TSB liquid culture medium and the Sa's liquid culture medium, so that the culture medium contains the multi-component organic acid and the saccharides.
4) Culturing: 190. mu.L of liquid medium was added to a 96-well plate, and 10. mu.L of the prepared bacterial suspension was added. Cultured for 48h and placed at OD600The absorbance was measured down, and the test was set up in triplicate, with the negative control being 1 × PBS.
The organic acid compositions are shown in table 2:
TABLE 2 organic acid combinations and ratios
The test shows that the 8 organic acid combination formulas B, C, D, F, G, H, I, J play a complete inhibition role on Escherichia coli, staphylococcus aureus, Streptococcus agalactiae and Candida albicans.
The 6 formulas A, B, C, D, E, F have inhibiting effect on lactobacillus crispatus, and the 4 organic acid combined formula G, H, I, J can shorten the time for lactobacillus crispatus to enter logarithmic phase, but after the lactobacillus crispatus enters stationary phase, OD (optical density) is increased600Lower than the negative control, as shown in FIG. 1. Therefore, when only organic acid in the lotion exerts the effect, the inhibition effect on harmful bacteria is influenced by different components and different proportions, and the growth of the harmful bacteria can be inhibited, but the growth of beneficial bacteria cannot be promoted.
Acid combinations H and I were selected for combination with glucose, trehalose and decyl glucoside, respectively, as in table 3:
TABLE 3 acid combinations and different saccharide combinations
The acid combination H and I, glucose, trehalose and decyl glucoside play a complete inhibition role in Escherichia coli, staphylococcus aureus, streptococcus agalactiae and candida albicans. The addition of glucose and trehalose has a promoting effect on the growth of lactobacillus crispatus, can shorten the time for lactobacillus crispatus to enter the logarithmic phase, and the addition of sunflower-based glucoside is properly supplemented on the basis of the addition of glucose or glucose and trehalose to effectively increase the number of cells of lactobacillus crispatus in the stationary phase, but the fact that the addition of sunflower-based glucoside alone does not promote the growth of lactobacillus crispatus is found, and the growth promoting effects generated by the sunflower-based glucoside and the sunflower-based glucoside need to be used together, as shown in fig. 2.
The combination of the organic acid composition with the saccharide and saccharide derivative composition is shown in table 3:
TABLE 4 combination of organic acid composition with saccharide and saccharide derivative composition
The 5 formulas K, L, M, N, O have complete inhibition effect on Escherichia coli, Staphylococcus aureus, Streptococcus agalactiae and Candida albicans. The combined formula of 5 organic acids and saccharide derivatives can shorten the time for lactobacillus crispatus to enter logarithmic phase. Wherein K, L two combinations have thallus OD after entering stationary phase600Is less negative thanControl, M, N, O thallus OD after stationary phase600Same as the negative control, as shown in FIG. 3. Therefore, when the small-molecule organic acid composition is combined with the saccharide and the saccharide derivative composition to perform a synergistic effect, the effects of inhibiting harmful bacteria and protecting and promoting the growth of beneficial bacteria can be realized.
The invention has the advantages and beneficial effects that: the external care agent obtained by the application utilizes the small molecular organic acid composition and the saccharide and saccharide derivative composition as core effect components, can balance a healthy gynecological micro-ecological flora structure, has an obvious sterilization effect on escherichia coli, staphylococcus aureus and streptococcus agalactiae, effectively inhibits genitourinary and urinary tract harmful bacteria such as escherichia coli, staphylococcus aureus and streptococcus agalactiae, has no obvious sterilization effect on candida albicans but inhibits the active growth of candida albicans, has an obvious bacteriostatic effect, is relatively small in the inhibitory effect on lactic acid bacteria compared with other pathogenic bacteria, and can promote the growth of probiotic lactobacilli in a genital tract by comprehensive use, thereby really playing a role in balancing the micro-ecological flora.
Drawings
FIG. 1 shows the effect of multiple components of organic acids in different ratios on the growth of Lactobacillus crispatus.
FIG. 2 is a graph showing the effect of the combination of organic acids and the combination formula of saccharides and saccharide derivatives of different components on the growth of Lactobacillus crispatus.
FIG. 3 shows the effect of the combination formula of organic acids with different proportions in the same component and saccharides and saccharide derivatives with different proportions in the same component on the growth of Lactobacillus crispatus.
FIG. 4 is a data statistics of the number of Escherichia coli colonies on a plate after 0 to 10 minutes of exposure to the wash formulation.
FIG. 5 is a data statistics of the number of Staphylococcus aureus colonies on the plates after 0 to 20 minutes of exposure to the wash formulation.
FIG. 6 is a data statistics of the number of Streptococcus agalactiae colonies on the plates after 0 to 10 minutes of exposure to the wash formulation.
FIG. 7 is a data set of the number of Candida albicans colonies on the plate after 0 to 60 minutes of exposure to the wash formulation.
FIG. 8 is a data statistics of the number of Lactobacillus crispatus colonies on a plate after 0 to 120 minutes of exposure to the wash formulation.
FIG. 9 is a data statistics of the number of Escherichia coli colonies formed on plates after 0 to 10 minutes of contact with the gel formulation.
FIG. 10 is a data statistics of the number of Staphylococcus aureus colonies on the plates after 0 to 20 minutes of contact with the gel formulation.
FIG. 11 is a data statistics of the number of Streptococcus agalactiae colonies on the plates after 0 to 10 minutes of contact with the gel formulation.
FIG. 12 is a data set of the number of Candida albicans colonies on the plate after 0 to 60 minutes contact with the gel formulation.
FIG. 13 is a data statistics of the number of Lactobacillus crispatus colonies on a plate after 0 to 120 minutes of contact with the gel formulation.
Detailed Description
The technical solution of the present application is described below with reference to the accompanying drawings and specific embodiments.
Example 1 table 1 formula table for washing solution No. 1
1) Adding water and sodium laureth sulfate into a main pot, and uniformly stirring; 2) adding pre-dispersed glycerol and xanthan gum into the mixed solution obtained in the step 1), and uniformly stirring; adding the acid composition and the composition of the sugar and the saccharide derivatives into the mixed solution obtained in the step 2), and uniformly stirring; 4) adding sodium benzoate into the mixed solution obtained in the step 3), and uniformly stirring.
Example 2
Table 2 washing liquid No. 2 formula table
1) Adding water and sodium laureth sulfate into a main pot, and uniformly stirring; 2) adding pre-dispersed glycerol and xanthan gum into the mixed solution obtained in the step 1), and uniformly stirring; adding the acid composition and the composition of the sugar and the saccharide derivatives into the mixed solution obtained in the step 2), and uniformly stirring; 4) adding sodium benzoate into the mixed solution obtained in the step 3), and uniformly stirring.
Example 3
Table 3 washing liquid No. 3 formula table
1) Adding water and sodium laureth sulfate into a main pot, and uniformly stirring; 2) adding pre-dispersed glycerol and xanthan gum into the mixed solution obtained in the step 1), and uniformly stirring; adding the acid composition and the composition of the sugar and the saccharide derivatives into the mixed solution obtained in the step 2), and uniformly stirring; 4) adding sodium benzoate into the mixed solution obtained in the step 3), and uniformly stirring.
Example 4
Table 4 washing liquid No. 4 formula table
1) Adding water and sodium laureth sulfate into a main pot, and uniformly stirring; 2) adding pre-dispersed glycerol and xanthan gum into the mixed solution obtained in the step 1), and uniformly stirring; adding the acid composition and the composition of the sugar and the saccharide derivatives into the mixed solution obtained in the step 2), and uniformly stirring; 4) adding sodium benzoate into the mixed solution obtained in the step 3), and uniformly stirring.
Example 5
Table 5 washing liquid No. 5 formula table
1) Adding water and sodium laureth sulfate into a main pot, and uniformly stirring; 2) adding pre-dispersed glycerol and xanthan gum into the mixed solution obtained in the step 1), and uniformly stirring; adding the acid composition and the composition of the sugar and the saccharide derivatives into the mixed solution obtained in the step 2), and uniformly stirring; 4) adding sodium benzoate into the mixed solution obtained in the step 3), and uniformly stirring.
Example 6
Table 6 gel No. 1 formula table
1) Adding water into the main boiler; 2) adding pre-dispersed glycerol and xanthan gum into water, and stirring; 3) adding the acid composition and the composition of the sugar and the saccharide derivatives into the mixed solution obtained in the step 2), and uniformly stirring; 4) adding sodium benzoate into the mixed solution obtained in the step 3), and uniformly stirring.
Example 7
Table 7 gel No. 2 formula table
1) Adding water into the main boiler; 2) adding pre-dispersed glycerol and xanthan gum into water, and stirring; 3) adding the acid composition and the composition of the sugar and the saccharide derivatives into the mixed solution obtained in the step 2), and uniformly stirring; 4) adding sodium benzoate into the mixed solution obtained in the step 3), and uniformly stirring.
Example 8
Table 8 gel No. 3 formula table
1) Adding water into the main boiler; 2) adding pre-dispersed glycerol and xanthan gum into water, and stirring; 3) adding the acid composition and the composition of the sugar and the saccharide derivatives into the mixed solution obtained in the step 2), and uniformly stirring; 4) adding sodium benzoate into the mixed solution obtained in the step 3), and uniformly stirring.
Example 9
Table 9 gel No. 4 formula table
1) Adding water into the main boiler; 2) adding pre-dispersed glycerol and xanthan gum into water, and stirring; 3) adding the acid composition and the composition of the sugar and the saccharide derivatives into the mixed solution obtained in the step 2), and uniformly stirring; 4) adding sodium benzoate into the mixed solution obtained in the step 3), and uniformly stirring.
Example 10
Table 10 gel No. 5 formula table
1) Adding water into the main boiler; 2) adding pre-dispersed glycerol and xanthan gum into water, and stirring; 3) adding the acid composition and the composition of the sugar and the saccharide derivatives into the mixed solution obtained in the step 2), and uniformly stirring; 4) adding sodium benzoate into the mixed solution obtained in the step 3), and uniformly stirring.
And selecting a No. 4 lotion product, a No. 5 lotion product, a No. 4 gel product and a No. 5 gel product for testing, wherein the specific operation is that 10 mu L of bacterial suspension is respectively sucked and placed in 90 mu L of undiluted lotion product and gel product, and the bacterial suspension is placed for different times. Treated samples were taken and left for different periods of time, diluted in 1 × PBS solution in a 10-fold gradient, and 100 μ L of the diluted sample was applied to the corresponding solid medium for culturing.
According to experimental data, after the product is contacted with the Escherichia coli for 6 minutes, the magnitude order of the Escherichia coli can be remarkably reduced by 4 magnitude orders, and the product has a remarkable sterilization effect on the Escherichia coli (such as figures 4 and 9); after the staphylococcus aureus is contacted with the staphylococcus aureus for 20 minutes, the number of the staphylococcus aureus can be reduced by one time, and the killing rate of the staphylococcus aureus is close to 50 percent (as shown in figures 5 and 10); after 6 minutes of contact with the streptococcus agalactiae, the magnitude of the streptococcus agalactiae can be reduced by 4 magnitude orders remarkably (such as fig. 6 and 11), and the streptococcus agalactiae has remarkable sterilization effect; after the candida albicans is contacted with the candida albicans for 60 minutes, the active growth of the candida albicans is inhibited, but no obvious bactericidal effect exists, the candida albicans is not remarkably sterilized, and only the bacteriostatic action is realized (as shown in figures 7 and 12). The lotion can still keep the same order of magnitude after instantaneous contact with the lactobacillus crispatus for 0 minute, 30 minutes and 60 minutes, and the lotion formula has no obvious antibacterial effect on the lactobacillus crispatus within 60 minutes of contact with the lactobacillus crispatus (such as figures 8 and 13). Therefore, when the small-molecule organic acid composition is used in combination with the combination of the saccharide and the saccharide derivative composition, the effects of inhibiting both harmful bacteria and protecting and promoting the growth of beneficial bacteria can be achieved.
Although the embodiments of the present invention have been described in detail, the description is only for the preferred embodiments of the present invention and should not be construed as limiting the scope of the present invention. All equivalent changes and modifications made within the scope of the present invention shall fall within the scope of the present invention.
Claims (9)
1. A nursing agent for balancing gynecological microecological flora structure comprises water, a surfactant, a humectant, a preservative and a thickening agent, and is characterized in that: the core efficacy component comprises a composition of small molecule organic acids and a composition of saccharides and saccharide derivatives.
2. A care agent for balancing the structure of gynaecological microecological flora according to claim 1, characterized in that: the paint comprises the following components in parts by weight: 1.5-5 parts of a small-molecular organic acid composition; 1.5-5 parts of a composition of saccharides and saccharide derivatives; 0-15 parts of a surfactant; 8-10 parts of a humectant; 0.5-1 part of a thickening agent; 0.8-1 part of preservative; 60-88 parts of water.
3. A care agent for balancing the structure of gynaecological microecological flora according to claim 2, characterized in that: the composition of the small molecular organic acid is the combination of at least two of lactic acid, acetic acid, butyric acid or citric acid.
4. A care agent for balancing the structure of gynaecological microecological flora according to claim 3, characterized in that: the composition of the small molecular organic acid in weight percentage is lactic acid (0.1%), acetic acid (0.1%) and butyric acid (0.1%) or lactic acid (0.5%), acetic acid (0.1%) and butyric acid (0.1%), lactic acid (0.5%) and citric acid (0.5%) or lactic acid (0.5%), citric acid (0.1%) and butyric acid (0.5%) or lactic acid (0.1%), acetic acid (0.5%) and butyric acid (0.5%) or lactic acid (0.1%), a combination of acetic acid (1%) and butyric acid (1%) or a combination of lactic acid (0.5%), acetic acid (0.5%) and butyric acid (1.5%) or a combination of lactic acid (0.5%), acetic acid (0.5%), butyric acid (1%) and citric acid (0.1%) or a combination of lactic acid (1.0%), acetic acid (1.5%) and butyric acid (0.5%) or a combination of lactic acid (1.0%), acetic acid (1%) and butyric acid (1%).
5. A care agent for balancing the structure of gynaecological microecological flora according to claim 4, characterized in that: the composition of the small molecule organic acid is, in weight percentage, a combination of lactic acid (0.5%), acetic acid (0.5%) and butyric acid (1.5%) or a combination of lactic acid (0.5%), acetic acid (0.5%), butyric acid (1%) and citric acid (0.1%) or a combination of lactic acid (1.0%), acetic acid (1.5%) and butyric acid (0.5%) or a combination of lactic acid (1.0%), acetic acid (1%) and butyric acid (1%).
6. A care agent for balancing the structure of gynaecological microecological flora according to claim 5, characterized in that: the composition of the small-molecule organic acid is a combination of lactic acid (1.0%), acetic acid (1.5%) and butyric acid (0.5%) or a combination of lactic acid (1.0%), acetic acid (1%) and butyric acid (1%) in percentage by weight.
7. The nursing agent for balancing gynecological micro-ecological flora structures according to any one of claims 1 to 6, characterized in that: the composition of the saccharides and saccharide derivatives is a combination of glucose, trehalose and decyl glucoside.
8. A care agent for balancing the structure of gynaecological microecological flora according to claim 7, characterized in that: the composition of the small molecular organic acid and the composition of the saccharide and the saccharide derivative are combined according to the weight percentage as follows: lactic acid (0.5%), acetic acid (0.5%), butyric acid (1.5%), glucose (0.5%), trehalose (0.5%) and decyl glucoside (0.1%) or lactic acid (0.5%), acetic acid (0.5%), butyric acid (1%), citric acid (0.1%), glucose (1%), trehalose (1%) and decyl glucoside (0.5%) or lactic acid (1.0%), acetic acid (1.5%), butyric acid (0.5%), glucose (1%), trehalose (1%) and decyl glucoside (0.5%) or lactic acid (1.0%), acetic acid (1%), butyric acid (1%), glucose (1%), trehalose (1%) and decyl glucoside (0.1%) or lactic acid (1.0%), acetic acid (1%), butyric acid (1%), glucose (0.5%), trehalose (1%) and decyl glucoside (0.1%).
9. A care agent for balancing the structure of gynaecological microecological flora according to claim 8, characterized in that: the composition of the small molecular organic acid and the composition of the saccharide and the saccharide derivative are combined according to the weight percentage as follows: lactic acid (1.0%), acetic acid (1%), butyric acid (1%), glucose (1%), trehalose (1%) and decyl glucoside (0.1%) or lactic acid (1.0%), acetic acid (1%), butyric acid (1%), glucose (0.5%), trehalose (1%) and decyl glucoside (0.1%).
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210047461.9A CN114306108A (en) | 2022-01-17 | 2022-01-17 | Nursing agent for balancing gynecological microecological flora structure |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210047461.9A CN114306108A (en) | 2022-01-17 | 2022-01-17 | Nursing agent for balancing gynecological microecological flora structure |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114306108A true CN114306108A (en) | 2022-04-12 |
Family
ID=81028349
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210047461.9A Pending CN114306108A (en) | 2022-01-17 | 2022-01-17 | Nursing agent for balancing gynecological microecological flora structure |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114306108A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114796173A (en) * | 2022-04-25 | 2022-07-29 | 上海森梅维斯药业有限公司 | Composition for regulating vaginal microecology by inhibiting vaginal harmful bacteria and protecting lactobacillus by using lactic acid and nursing method |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080193428A1 (en) * | 2005-04-27 | 2008-08-14 | Shenzhen Phlora Biotechnology Limited | Composition and Method for Modulating and Maintaining Vaginal Bacterial Flora and Vaginal Acidity |
CN106689671A (en) * | 2016-12-28 | 2017-05-24 | 新昌县赛因斯生物科技有限公司 | Biological bacterium-containing livestock feed and preparation method thereof |
CN109288793A (en) * | 2018-07-27 | 2019-02-01 | 江苏中天药业有限公司 | A kind of spray and preparation method thereof adjusted for vagina pH environment |
US20190231748A1 (en) * | 2016-10-09 | 2019-08-01 | Shenzhen Eulikan Biotechnology Co., Ltd. | Composition for vagina and antimicrobial agent combination for use in preparing composition for vagina |
CN112773780A (en) * | 2019-11-11 | 2021-05-11 | 深圳优丽康生物技术有限公司 | Composition for vagina and vulva and application thereof |
CN112933109A (en) * | 2021-02-03 | 2021-06-11 | 湖南奥朗特医疗器械有限公司 | Vagina pH regulator and preparation method and application thereof |
-
2022
- 2022-01-17 CN CN202210047461.9A patent/CN114306108A/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080193428A1 (en) * | 2005-04-27 | 2008-08-14 | Shenzhen Phlora Biotechnology Limited | Composition and Method for Modulating and Maintaining Vaginal Bacterial Flora and Vaginal Acidity |
US20190231748A1 (en) * | 2016-10-09 | 2019-08-01 | Shenzhen Eulikan Biotechnology Co., Ltd. | Composition for vagina and antimicrobial agent combination for use in preparing composition for vagina |
CN106689671A (en) * | 2016-12-28 | 2017-05-24 | 新昌县赛因斯生物科技有限公司 | Biological bacterium-containing livestock feed and preparation method thereof |
CN109288793A (en) * | 2018-07-27 | 2019-02-01 | 江苏中天药业有限公司 | A kind of spray and preparation method thereof adjusted for vagina pH environment |
CN112773780A (en) * | 2019-11-11 | 2021-05-11 | 深圳优丽康生物技术有限公司 | Composition for vagina and vulva and application thereof |
CN112933109A (en) * | 2021-02-03 | 2021-06-11 | 湖南奥朗特医疗器械有限公司 | Vagina pH regulator and preparation method and application thereof |
Non-Patent Citations (1)
Title |
---|
余㵑等: "医学微生物学", 人民卫生出版社, pages: 190 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114796173A (en) * | 2022-04-25 | 2022-07-29 | 上海森梅维斯药业有限公司 | Composition for regulating vaginal microecology by inhibiting vaginal harmful bacteria and protecting lactobacillus by using lactic acid and nursing method |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3520785B1 (en) | Uses of bacteriostatic agent formula in preparing composition for vaginal use and composition for vaginal use | |
CN105189733B (en) | Method for producing partially purified extracellular metabolites from bacillus coagulans and biological applications thereof | |
TWI405577B (en) | Antimicrobial agent | |
Guiot et al. | Partial antibiotic decontamination. | |
KR101287126B1 (en) | Pharmaceutical compositon prevention and treatment of vaginitis and urinary tract infection comprising fermented solution of plant-originated Lactic acid bacteria | |
CN103409334B (en) | Inhibit the Bacillus acidi lactici and application thereof of vaginitis pathogen | |
EP3548045B1 (en) | Compositions for use in the treatment of urogenital infections | |
KR101720145B1 (en) | Cosmetic composition for prevention and improvement of vaginosis | |
CN111084831A (en) | Bacteriostatic composition for inhibiting vaginal pathogenic bacteria and application thereof | |
CN114306108A (en) | Nursing agent for balancing gynecological microecological flora structure | |
CN111588723B (en) | Gynecological disinfectant and preparation method thereof | |
CH651205A5 (en) | COMPOSITION FOR FEMALE INTIMATE HYGIENE, PARTICULARLY FOR VAGINAL LAVENDERS. | |
EP3658131B1 (en) | Composition for the treatment of bacterial vaginosis | |
EP1481666B1 (en) | A composition for re-establishment of the vaginal ecosystem | |
KR20030037094A (en) | Antibiotic compositions comprising plant extract | |
CN115369061A (en) | Selective helicobacter pylori culture medium and preparation method thereof | |
RU2367454C1 (en) | Intime hygiene product "femivit" | |
CN115837068B (en) | Application of sodium surfactin, composition and application method thereof | |
KR20150075447A (en) | Cosmetic composition for prevention and improvement of vaginosis | |
CN116784446B (en) | Composition for synergistically inhibiting pseudomonas aeruginosa and application thereof | |
CN106902116A (en) | A kind of new opplication of rifamycin quinolizine ketone dual-target molecule | |
KR102430080B1 (en) | Antibacterial composition comprising methyl gallate and tylosin | |
CN118236395A (en) | Private protection antibacterial liquid and preparation method thereof | |
JP2018002661A (en) | Antibacterial antiseptic composition and composition prepared therewith | |
Al-Naama | Evaluation of inhibitory effect of honey on some bacterial isolates |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220412 |
|
RJ01 | Rejection of invention patent application after publication |